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Abstract
Acquired resistance to antiangiogenic drugs, such as sorafenib, is amajor clinical problem.Westudied development of
a resistance to sorafenib in new preclinical models of human hepatocellular carcinoma (HCC) along with a strategy to
delay such resistance—combination with metronomic chemotherapy. Three different xenograft models were studied
using human Hep3B HCC cells, which are highly responsive to sorafenib, namely, orthotopic and subcutaneous trans-
plant in severe combined immunodeficient mice, and an orthotopic transplant in nudemice. The complementary DNA
for the β-subunit of human choriogonadotropin was transfected into HCC cells, and urine levels of the protein were
monitored as a surrogate of tumor burden. Extended daily treatments, sometimes interrupted by a break period of 3 to
7 days to allow recovery from toxicity at sorafenib doses of 30 to 60mg/kg, weremaintained until and after evidence of
tumor relapse. Initially responsive tumors seemed to develop a resistance-like phenotype after long-term daily treat-
ment (e.g.,>42 days) at doses of 30 to 60mg/kg. Transplantation of cell lines established fromprogressing tumors into
new hosts showed that the resistant phenotype was not propagated. Furthermore, a regimen of daily metronomic
uracil + tegafur (UFT, an oral 5-fluorouracil prodrug) chemotherapy with a less toxic regimen of sorafenib (15 mg/kg
per day) significantly delayed the onset of resistance (>91days). In conclusion, development of a resistance-like pheno-
type to sorafenib is reversible, and metronomic UFT plus sorafenib may be a promising and well-tolerated treatment
for increasing efficacy by delaying emergence of such resistance.
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Introduction
The increasing and widespread clinical use of antiangiogenic drugs
has revealed that both intrinsic and acquired resistance to this new
clinical class of anticancer agent are significant problems that limit
their efficacy [1–3], similar to other classes of anticancer drug such as
chemotherapy, hormone or hormone receptor targeting therapies, and
oncogene-targeting signal transduction inhibitors. For example, the
progression-free survival or overall survival benefits induced by bevaci-
zumab, the anti–vascular endothelial growth factor (VEGF)monoclonal
antibody, when combined with chemotherapy are modest, that is, in the
range of 1 month to several months, based on randomized phase 3 clin-
ical trial results in metastatic colorectal, breast, and non–small cell lung
cancer [3]. Small-molecule tyrosine kinase inhibitors (TKIs) that target
VEGF and platelet-derived growth factor (PDGF) receptors, among
others, provide similar benefits as monotherapies for renal cell carci-
noma and hepatocellular carcinoma [2]. These results have stimulated
some empirical strategies to delay the onset of apparent acquired resis-
tance or to treat cancers that have progressed on antiangiogenic ther-
apy [2]. An example of such approaches includes sequential therapy
with different antiangiogenic drugs [4–6]. For example, renal cell can-
cer (RCC) patients whose tumors initially respond to sorafenib but
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later start progressing can sometimes respond again when treated with a
similar, but not identical, VEGF pathway–targeting drug, for exam-
ple, sunitinib [4,5]. A number of such sequential therapy approaches
are under investigation in the clinic [2,4].
Surprisingly, only a few preclinical studies have been reported thus
far dealing with the topic of acquired resistance to antiangiogenic drugs,
despite the obvious growing clinical importance of the phenomenon.
Such studies could clearly provide new insights into the mechanisms
underlying such resistance and thus strategies that might be considered
for either circumventing or delaying such resistance. The studies that
have been published suggest a number of possible, and diverse, mecha-
nisms of resistance such as “evasive resistance” whereby compensatory
proangiogenic pathways are induced or upregulated in tumor cells, such
as basic fibroblast growth factor–mediated tumor angiogenesis during
therapy with a drug that specifically targets the VEGF pathway, for ex-
ample, anti–VEGFR-2 antibodies [7]; this may occur as a consequence
of increased tumor hypoxia induced by the antiangiogenic drug treat-
ment [7,8]. If so, strategies to target the (elevated) hypoxia-inducible
factor 1α accompanying the increased hypoxia could represent a prom-
ising therapeutic approach to delay the resistant phenotype, for example,
by using metronomic chemotherapy regimens that target hypoxia-
inducible factor 1α [8–10]. Other suggested mechanisms of acquired
resistance include selection of tumor cell variants that can survive under
hypoxic conditions [11], rapid vascular remodeling resulting in more
mature vessels that are not responsive to antiangiogenic drugs [12,13],
and production of alternate proangiogenic growth factors such as
PDGF-C by cells in the stroma such as fibroblasts rather than the
tumor cells themselves [14]. With respect to intrinsic resistance to a
VEGF inhibitor, mobilization and tumor homing of proangiogenic
bone marrow–derived myeloid-type cells, which express CD11b, and
Gr1 has been proposed as a contributory mechanism [15], and as such,
could be involved in acquired resistance as well.
Interestingly, all of the aforementioned preclinical studies were under-
taken using protein-based drugs such as antibodies directed to VEGFR-
2 [7,11], or to VEGF itself, either using soluble VEGF receptor trap/
decoy drugs or anti-VEGF antibodies [14]. We are aware of two very
recent studies dealing with acquired resistance to oral small molecule
VEGF receptor multitargeting antiangiogenic TKIs, one by Hammers
et al. [16] and the other by Huang et al. [17]. Both deal with sunitinib.
In the former study, acquired resistance to sunitinib using a preclinical
model of human renal cell carcinoma xenografts was found to be due, at
least in part, to induction of interleukin 8–mediated tumor angiogenesis
[17]. In this case, the resistant phenotype seemed to be stable and heri-
table [17]. In contrast, the study byHammers et al. [16], using renal cell
carcinoma fragments from patients relapsing on sunitinib therapy that
were transplanted into immune-deficientmice, showed that the resistant
phenotype was unstable and was associated with a reversible epithelial-
to-mesenchymal phenotype.
The major purpose of this study was to develop an orthotopic pre-
clinical model of acquired resistance or a resistance-like phenotype to the
small molecule antiangiogenic TKI, sorafenib, in advanced human
hepatocellular carcinoma (HCC). Sorafenib, which targets all three
VEGF receptors and PDGF-B receptors, as well as some others, for ex-
ample, c-kit, flt3, ret, and raf kinases, has shown transient but statisti-
cally significant clinical benefits in advanced HCC in two large
randomized phase 3 trials [18,19] and is now approved for treatment
of this disease. To develop a model of development of sorafenib resis-
tance, we used three important procedures. First, we used a human
HCC line that is initially highly responsive to the drug, even when
orthotopically growing in the liver and treatment is initiated later at a
more advanced (established) stage of growth, rather than immediately
after transplantation of the cells [20]. Second, and perhaps most impor-
tantly, extended and effective treatments weremaintained until evidence
of onset of a more rapid progressive tumor growth (“relapse”) was ob-
served, indicative of the possible development of resistance to the drug.
Third, we monitored tumor response in the liver, and even subcutane-
ously, by a molecular surrogate biomarker approach, namely measuring
a protein secreted from the HCC cells—the β-subunit of human cho-
riogonadotropin (β-hCG), detected in the urine [21]. This was made
possible by transfecting a complementary DNA (cDNA) for β-hCG
into the HCC cells as previously described in other model systems
[21], similar to other studies using other human cell lines [22,23].
Here we report that cells of sorafenib-sensitive human HCC tumor
xenografts progressing on sorafenib after approximately 1 month or
more of daily treatment do not express the phenotype in a heritable
manner because it was completely lost when the cells were transplanted
to newhosts, whichwere then treatedwith sorafenib.We also report that
concurrent therapy using a nontoxic metronomic chemotherapy regi-
men with the drug UFT (uracil + tegafur), a 5-fluorouracil (5-FU) oral
prodrug [24], can significantly delay the onset of resistance to sorafenib
in the original (autochthonous) host, and do so without increasing overt
toxicity. The implications that some forms of a resistant-like phenotype
developing to a drug such as sorafenib not being stable are discussed.
Materials and Methods
Cell Lines
The human HCC cell line Hep3B was purchased from ATCC
(Manassas, VA). They were maintained in Dulbecco’s modified Eagle
medium (DMEM) with high glucose (Hyclone, Logan, UT) supple-
mented with 10% heat-inactivated fetal bovine serum (Hyclone), at
37°C in a humidified atmosphere containing 5% CO2. Hep3B cells
were transfected with the hCG.pIRES vector, and hCG-expressing
variants were obtained by puromycin selection. The hCG.pIRES vec-
tor carries the cDNA for β-subunit of human choriogonadotropin
(β-hCG), and the secreted protein can be detected in the urine as a
surrogate marker for tumor burden [21]. The Hep3B-hCG clone
was used for the experiment based on the highest levels of protein
expression. Cells were dissociated by trypsin, washed once in serum-
containing DMEM followed by two washes in serum-free DMEM,
and then resuspended in serum-free DMEM for implantation.
Animals
Female CB17 severe combined immunodeficient (SCID; Charles
River Canada,Quebec, Canada) or athymic nude (nu/nu) mice (Harlan,
Indianapolis, IN) aged between 6 and 8 weeks were used. All ani-
mals were housed in microisolator cages, and procedures were carried
out in accordance with institutional guidelines for proper animal care
and maintenance.
β-hCG Measurements
Urine β-hCG was measured with the commercially available Patho-
zyme Free β-hCG ELISA Kit (Omega Diagnostics Ltd, Scotland, UK),
which allows for quantitative determination of β-hCG. Urine β-hCG
levels were normalized by concomitant measurement of urine creatinine
levels (usingQuantiChromCreatinine assay kit from BioAssay Systems,
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Hayward, CA) as described previously by Shih et al. [21]. Urine was
collected by placing mice individually into small sterile aerated boxes
for 2 hours.
Subcutaneous (Ectopic) Transplantation of Human HCC Cells
Abolus of fivemillionHep3B-hCGcells was injected subcutaneously
into CB-17 SCID mice. Tumor size was assessed weekly by means of
Vernier calipers and the formula (w1 × w2 × w2) / 2, where w1 and w2
are the length and width (mm), respectively.
Orthotopic (Intrahepatic) Implantation of HCC Cells
Aseptic technique was used throughout the surgical procedure [20].
The anesthetized mouse was laid on its back, and a 1-cm transverse
incision was made through the skin and peritoneum of the left upper
abdomen. A portion of the liver was exposed by applying gentle pressure
on the abdomen. We injected 106 cells in a 10-μl volume into the sub-
sera of the liver by using a 25-μl Hamilton syringe and 30-gauge needle.
After swabbing the area with sterile gauze, the pressure was removed
from the abdomen, allowing the liver to slip back into place. The peri-
toneum was closed with 4-0 absorbable suture, and the skin was closed
with wound clips.
Drugs and Treatment Schedules Used
The antiangiogenic drug sorafenib tosylate, an oral multitargeting re-
ceptor TKI, was generously provided by Bayer (Leverkusen, Germany),
with the assistance of Dr. Scott Wilhelm. Known targets include all
three VEGF receptors, PDGF-B receptors, and B-Raf, c-KIT receptor,
and ret [25]. Sorafenib was prepared fresh daily just before gavaging,
by dissolving in cremorphor EL/95% ethanol/water (12.5:12.5:75) as
described previously [26,27]. The drug was administered by daily
gavage at dose levels of 15, 30, and 60 mg/kg body weight starting be-
tween days 12 and 14 when all animals in the study had evidence of
established tumors averaging from 100 to 150 mg based on β-hCG
values, with five mice per group.
For the metronomic chemotherapy treatments, UFT, an oral 5-FU
prodrug, which consists of a 4:1 molar combination of uracil (U) and
tegafur (FT) was used in 0.1% hydroxypropylmethyl cellulose [28,29].
UFT is a first-generation dihydropyrimidine dehydrogenase inhibitory
flouropyrimidine drug. Tegafur, uracil, and the hydroxypropylmethyl
cellulose were generously supplied by Taiho Pharmaceutical Co, Ltd
(Tokyo, Japan) with the assistance of Dr. Teiji Takechi. UFTwas pre-
pared fresh daily just before gavaging. The dosage of UFT used was
15/mg/kg per day administered by gavage. This was previously assessed
as an optimal biologic dose of the drug when given in a daily nonstop
metronomic fashion [24]. Cyclophosphamide (CTX; Baxter Oncology
GmbH,Mississauga, Ontario, Canada) was purchased from the institu-
tional pharmacy. CTX was reconstituted as per manufacturer’s instruc-
tions to a stock concentration of 20 mg/ml and administered through
drinking water to provide an estimated dosage of 20 mg/kg per day of
CTX based on the estimated daily consumption of 3 ml for a 20-g
mouse, as previously described [30].
Statistical Analysis
Results are reported as the mean ± SD. Statistical significance of dif-
ferences in the sorafenib therapy experiments was assessed by two-way
analysis of variance. Survival curves were generated by the Kaplan-Meier
method, and the statistical significance of differences in survival was
assessed by χ 2. All statistics was generated by using GraphPad Prism
4.00 software (GraphPad Software Inc., San Diego, CA). The level of
significance was set at P < .05. Statistical analyses were based on the
overall trend of the growth curves.
Results
Effect of Sorafenib Treatment on Tumors Derived from HCC
Cells Orthotopically Injected into SCID Mice
We developed an orthotopic model of HCC by implanting human
Hep3B cells in the livers of SCID mice as described in the Materials
and Methods and elsewhere [20]. To help monitor disease burden
and progression, the Hep3B cells were transfected with β-hCG cDNA,
which results in secretable protein that can be measured in urine as a
biomarker of tumor burden [20–23]. Next, we used this model to test
the antitumor effect of different sorafenib monotherapies, as well as
combinations of sorafenib withmetronomic chemotherapy (Figure 1A).
Three different doses of sorafenib were used for single-agent treatment,
a decision that was guided by previously published preclinical studies
reported by others [25–27,31]. We found sorafenib alone administered
at 60 mg/kg per day (Figure 1A) was toxic to SCID mice because it
caused a 10% body weight loss within the first 4 weeks of treatment
(Figure 1C). Treatment was therefore suspended and was subsequently
resumed only after the body weights of mice returned to the levels mea-
sured before treatment was begun. Lower doses of sorafenib that we
tested also caused toxicity. However, this became evident only after
much longer periods of treatment. Thus, sorafenib at 30 mg/kg per
day caused a 10% weight loss after 38 days of treatment (Figure 1C),
whereas using the 15-mg/kg per day regimen, this toxicity became evi-
dent only after 56 days of daily treatment. The combination of sora-
fenib (30 mg/kg per day) with metronomic oral CTX administered
through the drinking water at a dose of 20 mg/kg per day caused a
10% weight loss within 10 days of treatment, whereas for the combi-
nation of sorafenib (30mg/kg per day) withmetronomicUFT (15mg/kg
per day), weight loss of a similar magnitude became significant after
38 days of treatment. In previous studies, neither metronomic UFT
nor CTX, nor concurrent combination of the two drugs, caused signifi-
cant weight loss, even after more than 140 days of continuous daily treat-
ment of the combination [24]. Thus, whenever significant weight loss
was observed, only the administration of sorafenib was suspended (so
that in the combination therapy groups, the administration of the met-
ronomic CTX or UFTwas continued), and sorafenib treatment was
resumed when the mouse body weights recovered (Figure 1C ); these
sorafenib drug “holidays” ranged from 3 to 9 days in duration.
Preclinical Effect of Sorafenib Therapies on Orthotopic HCC
Growth as Assessed by Urine β-hCG Levels
Despite the difficulties that arose because of the toxicity associated
with sorafenib treatment in SCIDmice, the urine β-hCGdata suggested
a significant antitumor effect of the various regimens we tested. Thus,
after 1 week of daily treatment, we observed marked differences in the
β-hCG urine levels in the different groups (Figure 1A). The control
group’s β-hCG levels rose rapidly until day 35 (at which point, some
of the mice became moribund). In contrast, all the treatment groups
showed a delay in the increase of urine β-hCG levels. The highest
β-hCG levels within the sorafenib treatment groups were seen with
sorafenib monotherapy using the lowest dosage, that is, 15 mg/kg per
day (Figure 1A), whereas the lowest β-hCG levels were observed using
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the following regimens: 1) 60 mg/kg per day sorafenib, 2) 30 mg/kg
per day sorafenib plus UFT, and 3) 30 mg/kg per day sorafenib plus
CTX. The sudden drop in β-hCG levels in the 15-mg/kg per day sora-
fenib group on day 56 (Figure 1A) coincided with the death of one
mouse in this group before urine collection. Similarly, one mouse died
in the control group on day 42, and the remainingmice becamemoribund
3 days later; the control group was therefore terminated on day 45 (i.e.,
3 weeks after treatment initiation). For the 15-mg/kg per day sorafenib
monotherapy group, all the remaining mice also began to show weight
loss or manifested a moribund state by day 73, at which point mice from
this group were also killed. However, all the other treatment groups did
not show signs of advanced disease until day 84 (i.e., week 10 after treat-
ment initiation), at which point the experiment was terminated, andmice
from all groups were killed. The mean weights of tumor mass in the livers
of the mice at the time of sacrifice (Figure 1B) were consistent with the
β-hCG data. Thus, they showed that the sorafenib treatment regimens
caused a reduction in the tumor burden compared with controls. Taken
together, these results suggest that the sorafenib regimens are effective in
treating orthotopically implanted established Hep3B tumors, although
the prolonged sorafenib treatment regimens using the higher doses are
associated with significant host toxicity in SCID mice.
Effect of Sorafenib Treatment on Subcutaneous HCC Tumors
in SCID Mice
Hep3B cells were also injected subcutaneously in SCID mice to fur-
ther evaluate the effect of sorafenib treatment in this more conventional
model of therapy testing (Figure 2A). Furthermore, caliper measure-
ments of the subcutaneously growing tumors in this experiment al-
lowed us to confirm the reliability of the β-hCG marker as a readout
for relative tumor burden (Figure 2B). Similar to our observations
using the orthotopic tumor transplant model, we again noted that
the sorafenib monotherapies we tested (at 15, 30, or 60 mg/kg per
Figure 1. Effect of sorafenib regimens on orthotopically implanted human Hep3B HCC cells in SCID mice. Hep3B cells were tagged with
β-hCG and implanted into the left lobe of the liver (n= 5 per treatment group). (A) Urine β-hCG levels of pooled samples, normalized to urine
creatinine levels, of mice treated with sorafenib monotherapies (at 15, 30, or 60 mg/kg per day by gavage) or sorafenib (at 30 mg/kg per day)
combinedwith eithermetronomic CTX (20mg/kg per day, per os) ormetronomic UFT (15mg/kg per day by gavage). Treatmentswere carried
out during the periods indicatedwith breaks in sorafenib dosing startingwhen toxicity (i.e., >10%average bodyweight loss)was observed in
each treatment group. The graph shows the beneficial effect of the sorafenib regimens compared with controls treated by gavage of vehicle
alone, on the relative tumor burden. Green asterisk indicates a mouse treated with 15mg/kg per day of sorafenib that died at that time point.
Red asterisk indicates a mouse treated with 60 mg/kg per day of sorafenib that died at that time point. (B) Corresponding weight measure-
ments of the tumor mass in the liver of mice in each treatment group at the time of sacrifice (note that because of the different treatment
efficacies,mice from the groupswere killed at differentweeks after the initiation of treatment, as indicated). (C) Correspondingmouseweight
curves as a measure of relative toxicity of the different sorafenib treatment regimens. Note that for individual groups, sorafenib treatment
was suspended for the indicated times whenever toxicity was observed in each group.
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Figure 2. Effect of sorafenib regimens on subcutaneously implanted Hep3B cells in SCID mice. Hep3B cells were tagged with β-hCG and
implanted into the left flank of SCID mice (n = 5 per treatment group). (A) Urine β-hCG levels of pooled samples, normalized to urine crea-
tinine levels, of mice treated with sorafenib monotherapies (at 15, 30, or 60 mg/kg per day by gavage). Treatments were carried out during
the periods indicated with breaks in sorafenib dosing starting when toxicity (i.e., >10% average body weight loss) was observed in each
treatment group. The graph shows the beneficial effect of the sorafenib regimens, compared with controls treated by gavage of vehicle
alone, on the relative tumor burden. (B) Corresponding tumor volume curvesmirror the beneficial effect of the sorafenib regimens compared
with controls. (C) Correspondingweight measurements of the tumormass ofmice in each treatment group at the time of sacrifice (note that
because of the different treatment efficacies, mice from the groups were killed at different weeks after the initiation of treatment, as indi-
cated). (D) Corresponding mouse weight curves as a measure of relative toxicity of the different sorafenib regimens. Note that for individual
groups, sorafenib treatment was suspended for the indicated times whenever toxicity was observed in each group.
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day) significantly inhibited tumor growth compared with vehicle-
treated controls (Figure 2A). The β-hCG curves obtained were found
to be in good agreement with the more traditional tumor caliper mea-
surements (Figure 2B), as well as with the mean weight of the tumor
mass in the mouse livers when the experiment was terminated, as
shown in Figure 2C . Note that because of the different treatment
efficacies, mice from the various groups were killed at different times
after the start of treatment, as indicated. However, once again, we
found that the antitumor benefit of the sorafenib treatments came at
the expense of toxicity, which emerged after prolonged drug adminis-
tration schedules (Figure 2D, with the exception of the 15-mg/kg per
day treatment group). Because of this treatment-associated weight loss,
we again had to interrupt sorafenib administration for periods ranging
from 5 to 7 days (Figure 2D) in the 30- or 60-mg/kg per day treatment
group. In conclusion, sorafenib is effective for the treatment of es-
tablished primary Hep3B tumors in SCID mice, but the treatment-
associated toxicity in such mice necessitated occasional short breaks
in therapy. Also notable are the marked antitumor effects observed,
Figure 3. Comparison of slopes of early phase responding tumors and during the later relapse phase of tumor “relapse” of Hep3B sub-
cutaneous tumors in SCID mice. Upper panel shows the slopes of tumor growth curves based on tumor volume measurements. (A) The
slope of the early phase tumor volume growth curve from day 7 to 38 in the 30-mg/kg per day of sorafenib-treated mice. (B) Slope of the
relapse phase of the tumor volume growth curve, fromday 42 to 84 in 30mg/kg per day of sorafenib-treatedmice. (C) Slope of the early phase
of the tumor volume growth curve from day 7 to 38 in the 60-mg/kg per day of sorafenib-treated mice. (D) Slope of the relapse phase of the
tumor volume growth curve from day 42 to 84 in 60mg/kg per day of sorafenib-treatedmice. Lower panel shows the slopes, based on β-hCG
growth curves. (E) Slope of the early phase of the β-hCG curve from day 7 to 35 in the 30-mg/kg per day of sorafenib-treatedmice. (F) Slope of
the relapse phase of the β-hCG curve from day 42 to 84 in the 30-mg/kg per day sorafenib-treated mice. (G) Slope of the early phase of the
β-hCG growth curve from day 7 to 35 in the 60-mg/kg per day of sorafenib-treated mice. (H) Slope of the relapse phase of the β-hCG growth
curve from day 42 to 84 in the 60-mg/kg per day of sorafenib-treated mice.
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as measured by β-hCG levels or tumor volumes, which were main-
tained for 40 to 50 days of treatment but were then followed by the
onset of a more progressive tumor growth—an observation that is gen-
erally considered a classic manifestation of (acquired) drug resistance.
An important question is whether the rate of growth when tumors
seem to start relapsing on sorafenib therapy is faster than when re-
sponding during the first month or so of drug treatment. This would
be indicative of onset of tumor “progression” and hence the probable
development of resistance. Simple visual inspection of the growth curves
in the therapy experiments would seem to indicate that this is so.
Nevertheless, we calculated the slopes of the Hep3B tumor growth
curves in the subcutaneous transplant model based on both tumor
volumes and β-hCG measurements, in drug-treated mice, during the
“early” phase of responsive tumor growth and the later “relapse” phase.
The results in Figure 3 show steeper slopes indicative of more rapid
tumor growth during the later phase, using both types of measurement.
Also of interest, the relative changes in growth were assessed to be very
similar whether tumor volumes or β-hCG measurements were used
for the calculations—another indication that secreted β-hCG can be
used as a valid surrogate molecular biomarker of tumor burden/growth.
In Table 1, we show the relative slope values and fold changes in growth,
which indicate a pronounced increase in tumor growth rates between
the initial responding phase and then the “nonresponding” phase in
subcutaneous transplant model.
Acquired Resistance-like to Sorafenib Does Not Appear to Be
a Heritable Phenotype In Vivo
To investigate the nature of the acquired resistance-like to sorafenib
that became apparent during the course of our therapy studies, we iso-
lated cells from tumors relapsing on therapy in both our orthotopic
and subcutaneous models. Thus, tumors apparently relapsing to sora-
fenib monotherapy at 30 mg/kg per day on day 85 in the orthotopic
model were removed and adapted to tissue culture during 2 weeks,
and the resulting cell line was termed Nex30-OT1. Similarly, a cell line
termed Nex60-OT was derived from tumors relapsing on sorafenib
monotherapy at 60 mg/kg per day on day 85. From the subcutaneous
tumors, Nex30-SC and Nex60-SC cell lines were derived from tumors
relapsing on sorafenib monotherapies of 30 and 60 mg/kg per day,
respectively. We next asked whether the resistance-like phenotype to
sorafenib was heritable. To answer this question, the cell lines from pre-
viously mentioned progressing tumors were injected orthotopically into
new hosts. We treated these mice by using 30 or 60 mg/kg per day of
sorafenib or vehicle control for up to 56 days. We did not detect any
evidence of resistance to sorafenib in any of the treatment groups (Fig-
ure 4). However, the same toxicity effect observed in earlier experiments
was found, that is, weight loss occurred in all treatment groups, and es-
pecially severe was the weight loss in the 60-mg/kg per day sorafenib
group. Thus, what seems to be acquired resistance to sorafenib did
not seem to be stable (propagatable) in vivo, when the cells were trans-
ferred to new hosts.
Effect of Sorafenib Monotherapy on Orthotopic Hep3B
Tumors in Nude Mice
SCID mice seem to be hypersensitive to sorafenib therapy, which
hampered long-term administration of the drug. This is not an effect
that is restricted to sorafenib as we have observed similar hypersensitivity
to other TKIs such as sunitinib. Therefore, we decided to use the same
HCCmodel in nudemice where we speculated toxicity would be less of
an issue. Hep3B were implanted into the livers of nude mice, which
were then treated 14 days later with control vehicle alone or with sora-
fenib monotherapy (at 30 or 60 mg/kg per day; Figure 5A).
The weight loss observed in the nude mice in this experiment (Fig-
ure 5B) was less severe than that observed in SCID mice (Figure 1A).
Nonetheless, some of the nude mice in the 60-mg/kg per day sorafenib
treatment group experienced a 10% weight loss at day 84 (i.e., after
70 days of continuous treatment). In addition, one mouse died in the
30-mg/kg per day sorafenib group, and three died in the 60-mg/kg per
day group without showing previous signs of overt toxicity (Figure 5A).
Some of the mice in both treatment groups developed a transient and
moderate rash after 1 week of treatment, which was more severe 4 weeks
later. The β-hCG levels in the treatment groups (Figure 5A) showed
a similar pattern to that observed in the HCC model in SCID mice
(Figures 1A and 2A), that is, a pronounced antitumor effect induced
by the sorafenib regimens. Thus, sorafenib is effective in inhibiting
Table 1. Slopes of Tumor Growth Curves of Early and Relapse Phases in the Subcutaneous Hep3B SCID Mice Model.
Slope between Days 7 and 35 (Early Phase) Slope between Days 42 and 84 (Relapse Phase) Fold Change ×
30 mg/kg per day sorafenib (tumor volume) 5.32 10.518 1.97×
60 mg/kg per day sorafenib (tumor volume) 1.66 12.887 7.76×
30 mg/kg per day sorafenib (β-hCG) 0.0171 0.2058 12×
60 mg/kg per day sorafenib (β-hCG) 0.0092 0.3352 36×
Figure 4. Effect of sorafenib regimens on orthotopically implanted Hep3B variants derived from tumors that developed resistance to
sorafenib. The cell lines shown in this figure are from a single tumor from each treatment group, and these were implanted into the left
lobe of the liver of SCID mice (n = 5 per treatment group). The variants tested are (i and ii) Hep3B parental cells, (iii and iv) Nex30-OT1 (a
cell line obtained from an orthotopic tumor that relapsed on 30 mg/kg per day sorafenib), (v and vi) Nex60-OT (a cell line obtained from an
orthotopic tumor that relapsed on 60 mg/kg per day of sorafenib), (vii and viii) Nex30-SC (a cell line obtained from a subcutaneous tumor
that relapsed on 30 mg/kg per day of sorafenib), and (xi and x) Nex60-SC (a cell line obtained from a subcutaneous tumor that relapsed on
30 mg/kg per day of sorafenib). Left panels: Urine hCG levels of pooled samples, normalized to urine creatinine levels, of mice treated with
sorafenib monotherapies (at 30 or 60 mg/kg per day by gavage). Compared with control, both sorafenib regimens impaired the growth of
the various Hep3B variants comparable to parental Hep3B. Right panels: Corresponding mouse weight curves as a measure of relative
toxicity of the different sorafenib regimens.
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Hep3B tumor growth in both SCID and nude mice, and this benefit is
associated with less toxicity in nude mice.
Effect of Combining Sorafenib with Daily Metronomic UFT
We previously evaluated combining sorafenib (at a dose of 30 mg/kg
per day) with metronomic UFT (15 mg/kg per day) and observed some
increased toxicity (compared with UFT alone—data not shown), after
40 days of therapy with no breaks (Figure 1). Thus, the toxicity seems to
be caused by the sorafenib component of the combination treatment.
We therefore decided to test a lower dose of sorafenib (15 mg/kg
per day) in combination with metronomic UFT chemotherapy. The
rationale was that this combination treatment might have a much supe-
rior therapeutic ratio, that is, reduced toxicity (thus leading to more ex-
tended therapy) accompanied by similar or improved antitumor efficacy.
Hep3B cells were implanted orthotopically into SCID mice and then
treated with sorafenib or UFTmonotherapy (15 mg/kg per day each)
or with sorafenib plus metronomic UFT.
The urine β-hCG data curves in this experiment indicated that the
combination of sorafenib plus metronomic UFTwas highly effective
at inhibiting tumor growth (Figure 6A), whereas the respective mono-
therapies were less effective. The benefit of the sorafenib plus metro-
nomic UFT in this model was confirmed by superior median survival
Figure 5. Effect of sorafenib regimens on orthotopically implanted Hep3B-hCG cells in nudemice. Green asterisk indicates a mouse treated
with 30 mg/kg per day of sorafenib that died at that time point. Red asterisk indicates a mouse treated with 60 mg/kg per day sorafenib that
died at that time point. (A) Urine hCG levels of pooled samples, normalized to urine creatinine levels, of mice treated with sorafenib mono-
therapies (at 30 or 60mg/kg per day by gavage). Hep3-hCG tumor growth impairment by sorafenib is similar to the effects seen in SCIDmice.
(B) However, corresponding mouse weight curves as a measure of relative toxicity reveal a lower degree of toxicity in nude compared with
SCID mice.
Figure 6. Effect of reduced-dose sorafenib combinedwithmetronomicUFT on orthotopically implantedHep3B–β-hCGcells in SCIDmice (n=
5 per treatment group). (A) Urine β-hCG levels of individual mice, normalized to urine creatinine levels, treated with sorafenib alone (15 mg/kg
per day),metronomic UFT alone (15mg/kg per day), or sorafenib andmetronomicUFT combination therapy (15mg/kg per day each). Although
the benefit of the corresponding monotherapies is modest, sorafenib and metronomic UFT combination therapy delays the occurrence of
treatment resistance. (B) Kaplan-Meier survival curves confirm the superior treatment benefit of the combination regimen, whereas no signifi-
cant weight loss is observed. (C) MS indicates median survival.
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(Figure 6B), which, importantly, was not compromised by any signifi-
cant host toxicity associated with the combination treatment regimen
(Figure 6C ). Thus, of all the treatments tested in this series of studies,
the metronomic UFT/sorafenib combination seemed to be the most
effective in terms of both efficacy and (reduced) toxicity.
Discussion
The increasing marketing approvals and clinical uses of antiangiogenic
drugs such as bevacizumab, sorafenib, sunitinib, and pazopanib high-
light the need for developing preclinical models designed to study the
basis of intrinsic or acquired resistance to such agents, both of which
are common occurrences in patients which limit their efficacy [1–3].
Although a number of such preclinical resistance models have been de-
scribed for antibody or other protein-based antiangiogenic drugs (see
Introduction), only two currently exist for the oral small-molecule anti-
angiogenic TKIs, and both involve sunitinib and renal cell carcinoma
[16,17]. Hence, our study adds to this small but important body of
literature and, moreover, is the first to deal with sorafenib and HCC.
In this regard, it is noteworthy that our results indicate what seems to
be a reversible (i.e., nonpropagatable) form of resistance-like phenotype
to sorafenib. Our results seem to be a classic manifestation of the devel-
opment of drug resistance on therapy, in which treated tumors show
an initial robust tumor response and then “progressive disease” at a later
time point. Detecting this response was made possible, or facilitated,
by three important technical considerations: 1) an HCC tumor line
(Hep3B) that is highly sensitive, at least initially, for over a month to
sorafenib therapy; 2) the use of a surrogate molecular marker, namely,
secreted β-hCG to monitor tumor growth, response, and then progres-
sion over time in the orthotopic model; and 3) the application of ex-
tended therapy regimens lasting at least until evidence of a tumor
relapse-like effect becomes evident with more rapid resumption of
tumor growth. Below we discuss some of the critical aspects, including
caveats, of the models we developed, the results obtained, as well as
some of the clinical implications of the results.
Effect of Sorafenib Treatment Interruptions
Because of the rapid in vivo growth of the Hep3B model [20], we
initiated treatment as soon as the disease was detectable by urine hCG
levels. A possible caveat of our models was the necessity to interrupt
the daily sorafenib treatments using the 30- or 60-mg/kg doses because
of toxicity (as manifested by loss of body weight ≥10%). However, such
interruptions are not uncommon in the clinic, sometimes occurring
in as many as 30% to 50% of metastatic cancer patients receiving sora-
fenib or other similar TKI drugs [19,32–35]. Thus, in a sense, our mod-
els, some of which also involve orthotopic tumor transplants, mimic
the clinical situation in a more faithful way than only using continuous
(and very short term) treatments of only subcutaneous tumor model
transplants. Nevertheless, future preclinical experiments designed to
investigate in greater depth the effect of discontinuous versus continu-
ous treatment regimens on outcomes, including drug resistance, would
seem warranted.
With respect to the toxicities encountered, it would seem that SCID
mice are especially sensitive to the toxicity of the sorafenib treatments.
This is not a sorafenib specific effect as we have observed similar results
with a number of other TKIs such as sunitinib (Ebos et al., unpublished
observations). SCID mice, because of a mutational defect of DNA-
dependent protein kinase, are known to be hypersensitive to certain
anticancer treatments involving DNA damage such as radiation [36].
The basis for the apparent hypersensitivity of SCID mice to TKI drugs
such as sorafenib, sunitinib, but apparently not others such as lapatinib
[37], remains to be determined.
Apparent Reversibility of the Phenotype of Acquired
Sorafenib Resistance
The experiments designed to evaluate the stability of the apparent re-
sistance to sorafenib, which developed after at least 1 month of daily
therapy (with a short interruption during the therapy), indicate an ap-
parent reversibility of the phenotype, as assessed by retransplantation
and treatment of the tumor cells in new hosts. One technical issue about
this experiment is that the tumors relapsing on sorafenib therapy in the
original treatment host were removed and cultured for at least 2 weeks,
after which the cells were injected into new hosts, and then sorafenib
treatment initiated after approximately 2 weeks (on the established pri-
mary tumors). This means that the “resistant” cells were not exposed to
sorafenib for about 1 month before they were exposed to treatment
again. It may be that continuous exposure to drug is necessary to main-
tain the resistant phenotype [38]. If so, treatment interruptions might
actually slow the development of resistance. One important implication
of this possibility is that tumors in patients relapsing on sorafenib might
respond again to the same drug after a defined break period, provided, of
course, that progression of such tumors is relatively slow. There is some
preliminary evidence that RCC tumors in patients who stop responding
to sorafenib may respond to a later treatment of a similar drug, for ex-
ample, sunitinib [2,4,5]. On the basis of our results, it may be that these
patients might have also responded to sorafenib again. These specula-
tions simply reinforce the need to study the apparent reversible nature
of the sorafenib drug resistance phenotype that may occur in some in-
stances and the effect of treatment interruptions on the kinetics of re-
sistance and (re)response. In this regard, we would note the recent
report by Hammers et al. [16] who found that xenografts established
from a biopsy of an RCC patient who had progressed on sunitinib after
showing an initial response, regained sensitivity to the drug, and that
this was associated with a reversible epithelial-to-mesenchymal pheno-
typic transition. Thus, our results are operationally and conceptually
similar to those of Hammers et al., despite using HCC cell lines and a
different drug.
Implications of Addition of Concurrent
Metronomic Chemotherapy
The kinetics of the resistance to sorafenib in our model facilitated an
experimental analysis of one possible strategy to delay the onset of such
resistance. Our preliminary results using a lower, less toxic, dose of sora-
fenib (15 mg/kg) with metronomic UFTare encouraging in this regard
because the combination provided the best therapeutic results of all
the various treatments we assessed and, moreover, did so in the absence
of any overt toxicity. This result, although preliminary, deserves further
investigation because sorafenib treatments at current recommended
doses can cause a plethora of toxic adverse effects in patients [39,40],
which, as already discussed, can lead to interruptions in therapy and/or
reductions in drug dose [19,32–35]. If the dose of sorafenib can be low-
ered by combination with another drug treatment known to be mini-
mally or nontoxic in the clinic, for example, metronomic UFT, which
has been used in a daily dosing (and uninterrupted) schedule for 2 years
in adjuvant treatment settings [28,41], such a combination protocol
would seem ideal for clinical evaluation with sorafenib. This could
be particularly worthwhile for the postoperative adjuvant treatment
of RCC or HCC. An additional rationale for this consideration, aside
938 Preclinical Model of Sorafenib Resistance in HCC Tang et al. Neoplasia Vol. 12, No. 11, 2010
from the precedents of randomized phase 3 clinical trial successes of
adjuvant metronomic UFT in non–small cell lung cancer [28] and
breast cancer [41] is that the addition of the metronomic chemother-
apy may prevent the possible tumor growth promoting effects of anti-
angiogenic TKIs in adjuvant-like treatment settings that were recently
described by us in preclinical studies [42].
The decision to emphasize UFT for metronomic chemotherapy
for HCC in our studies with sorafenib might be questioned in view
of some clinical results showing UFT does not have activity in advanced
HCC [43]. However, there are other reports indicating UFTmay have
such activity in advanced HCC [44,45]. Furthermore, an antitumor
effect of UFTmay become more evident when it is combined with an-
other drug such as sorafenib, especially in the postoperative adjuvant
setting of HCC where low tumor volumes are present [46]. Indeed,
although these preclinical studies were being completed, a clinical re-
port of a phase 2 trial involving treatment of HCC patients with sora-
fenib and metronomic UFT was published, showing encouraging
results, in terms of both clinical benefit and safety/tolerability [47].
In summary, our results suggest that the development of a resistant-
like phenotype in HCC cells to sorafenib seems to be reversible. Al-
though the mechanistic basis of this reversible phenotype is unknown,
it is likely to result from the fact that sorafenib is mainly targeting a host
process—tumor angiogenesis—rather than directly directing the tumor
cell population. The reversible phenotype has a number of implications
in the clinic, as we have discussed; finally, we have outlined a possible
strategy, based on preliminary results, that seems effective in delaying the
development of resistance to sorafenib, but without added toxicity—
concurrent metronomic chemotherapy, in this case using oral UFT.
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